Blinatumomab for Treatment of Refractory Myasthenia Gravis
Status:
NOT_YET_RECRUITING
Trial end date:
2028-06-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of Blinatumomab in the treatment of refractory myasthenia gravis, with the expectation of offering a new therapeutic option for refractory patients. The main questions it aims to answer are:
* Does Blinatumomab improve patients' clinical symptoms?
* Is Blinatumomab safe for the treatment of myasthenia gravis?
Participants will:
* Receive two cycles of intravenous Blinatumomab infusion, each lasting 5 days, with a 1-week interval between cycles.
* Visit the clinic once every 4 weeks for checkups and tests.
* Keep a diary of their symptoms and the types and dosages of medications.